Reaction: Cathie Wood on CRISPR & Genomic Stocks

Reaction: Cathie Wood on CRISPR & Genomic Stocks

Andrew O’Donnell discusses Cathie Wood's investment focus on genomics and CRISPR gene editing. It highlights the potential growth in the genomic market, estimated to reach $32 billion by 2032, and Wood's early investment in CRISPR companies. The video emphasizes the importance of having a team with expertise in both science and finance, illustrating their ability to make informed decisions in cutting-edge technologies. Success stories in gene editing, such as treatments for sickle cell disease, are mentioned, contrasting their market valuation with larger tech companies like Apple. Ethical concerns, including the controversy over gene-edited babies, are also discussed. The video concludes by underscoring the need for continued investment and research in genomics, acknowledging Wood's significant role in this field.

#GenomicsRevolution #CRISPREditing #DNAInnovation #CathieWoodInvestments #FutureOfGenetics #BiotechTrends #GeneTherapy #ScientificBreakthrough #GeneticEngineering #HealthcareInvestment #ArkInvest #BioTechFinance #CuttingEdgeScience #CRISPRtech #GeneEditingFuture #MedicalRevolution #BiotechStocks #GenomicInvesting #LifeSciences #GeneticDiscovery

[gerrycaragayan]

For me, i like her research, it has a basis, sometimes not realized yet. I think she makes sense.

[michaele.strasser]

I'm sure you know how hard it is to become not cynical seeing someone like her still in the media and talking about investments?

[TheTobacko]

INVITAE is my absolute favorite healthcare company